WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic Virus Products
Shots:
- WuXi ATU to provide overall process development- viral bank manufacturing- viral stock characterization and cGMP commercial manufacturing and IND filing services via its Oncolytic Virus CDMO platform- to accelerate the development and commercialization of Gene Medicine's oncolytic virus products
- The collaboration allows GeneMedicine to advance its pipeline products from the clinical stage to commercialization by utilizing WuXi ATU’s platform covering all types of products with high quality that obey global standards
- The collaboration is the first international CMC development and manufacturing project- emboldened by the Oncolytic Virus CDMO platform- jointly operated by WuXi ATU and GeneSail Biotech since Aug’2019
Click here to read full press release/ article | Ref: PRNewswire | Image: WuXi ATU
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com